Clinical Trials
371
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (251 trials with phase data)• Click on a phase to view related trials
Implementation of the MOX Activity Monitor in Hospitalized Geriatric Rehabilitation
- Conditions
- Hip FractureStrokeFraility
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- KU Leuven
- Target Recruit Count
- 40
- Registration Number
- NCT07124247
- Locations
- 🇧🇪
UZ Leuven, campus Pellenberg, Pellenberg, Belgium
Model-based Medication Dosing Assist for Tacrolimus in Kidney Transplantation
- Conditions
- Kidney Transplantation
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- KU Leuven
- Target Recruit Count
- 357
- Registration Number
- NCT07030660
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Belgium
The Effects of Exogenous Ketosis on Ultra-endurance Recovery and Performance
- Conditions
- Exogenous KetosisEndurance Cycling PerformanceFatigue; Muscle, HeartFatigue, Mental
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- KU Leuven
- Target Recruit Count
- 24
- Registration Number
- NCT06965491
- Locations
- 🇧🇪
KU Leuven, Leuven, Vlaams-Brabant, Belgium
ABC School Intervention Among Ugandan Adolescents
- Conditions
- AnxietyDepression Disorders
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- KU Leuven
- Target Recruit Count
- 2598
- Registration Number
- NCT06957925
- Locations
- 🇺🇬
School, Masaka, Uganda
The Impact of Daily Intake of Short-chain Fatty Acids on Cardiometabolic Risk Factors in Individuals at Risk for Metabolic Syndrome
- Conditions
- Energy ExpenditureMetabolic SyndromeAnthropometryBody CompositionGlycemiaLipaemiaMetabolomicsBlood Pressure
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- KU Leuven
- Target Recruit Count
- 50
- Registration Number
- NCT06951386
- Locations
- 🇧🇪
KU Leuven/ UZ Leuven, Leuven, Vlaams-Brabant, Belgium
- Prev
- 1
- 2
- 3
- 4
- 5
- 69
- Next
News
KU Leuven Spin-off Hemastatx Develops First Therapy Targeting Root Cause of Severe Bleeding Disorder
Hemastatx, a new KU Leuven spin-off, has developed the first therapy to address the underlying mechanism of von Willebrand factor defects, a severe bleeding disorder affecting 100,000 hospitalized patients annually worldwide.
KU Leuven Researchers Develop Dual-Agent Method to Permanently Silence HIV Virus
Researchers at KU Leuven have developed a novel dual-agent approach that renders HIV permanently harmless by forcing the virus into a deep dormant state.
eXmoor Pharma and KU Leuven Form Strategic Alliance to Accelerate AAV Gene Therapy Development
eXmoor Pharma and KU Leuven have established a strategic partnership to support a new cell and gene therapy hub, focusing on accelerating AAV gene therapies from bench to first-in-human trials.
KU Leuven and UZ Leuven Launch €14 Million Advanced Therapy Production Facility
KU Leuven and UZ Leuven are investing €14 million to establish an Advanced Therapy Medicinal Products (ATMP) facility on the Gasthuisberg campus, scheduled to be operational by late 2025.